- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02443519
Bronx MBCT-Migraine (BMBCT-M)
17 septembre 2020 mis à jour par: Elizabeth Seng, Albert Einstein College of Medicine
Bronx Mindfulness Based Cognitive Therapy for Migraine: a Randomized Clinical Trial
This randomized clinical trial aims to examine the effect of a standardized 8-week course of Mindfulness Based Cognitive Therapy for Migraine on migraine-related disability in people with migraine.
Aperçu de l'étude
Type d'étude
Interventionnel
Inscription (Réel)
60
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
New York
-
Bronx, New York, États-Unis, 10461
- Yeshiva University
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 65 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- ICHD-3 beta headache diagnosis of migraine,
- self-reported and diary-confirmed 4-20 headache days per month
- aged 18-65
- ability to read English
- capacity to consent.
Exclusion Criteria:
- no ICHD-3 beta headache diagnosis of migraine
- fewer than 4 or greater than 20 headache days per month
- under 18 or over 65
- inability to read English
- lacking the capacity to consent
- utilization of new preventative pain treatments within four weeks of the baseline assessment, or a plan to utilize new preventive pain medications during the duration of the study
- severe psychiatric illness that would interfere with participation in the treatment
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: MBCT for Migraine
In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn).
Participants will attend weekly 75-90 minute individual sessions for eight weeks.
At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain).
Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc).
Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
|
8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
|
|
Aucune intervention: Wait List/Treatment as Usual
Patients will continue with standard care.
Patients will be offered MBCT after the primary endpoint.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of People With "Severe" Scores on the Migraine Disability Assessment
Délai: Change from Month 1 to Month 4
|
The MIDAS is a 5-item, self-report instrument that assesses the number of days in the past three months participants experienced partially or fully reduced functioning in a variety of contexts (work, school, social).
MIDAS scores are totaled and interpreted in the following grades: 0-5 = Grade I (Little or no disability); 6-10 = Grade II (Mild disability); 11-20 = Grade III (Moderate disability); 21+ = Grade IV (Severe disability).
Scores were dichotomized at "Not Severe" (Grades I, II, and III) and "Severe "(Grade IV).
The outcome was the proportion of participants who reported "Severe Disability."
|
Change from Month 1 to Month 4
|
|
Headache-Related Disability Index
Délai: Change from Month 1 to Month 4
|
25-item, self-report questionnaire of the emotional and functional impact of headache on daily activities.
Total scores range from 0-100, with higher scores indicating higher levels of disability.
|
Change from Month 1 to Month 4
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Headache Days (Over Course of 1 Month)
Délai: Change from Month 1 to Month 4
|
Number of headache days/month for the month prior to treatment, and the month after treatment
|
Change from Month 1 to Month 4
|
|
Average Headache Severity for Headache Days Recorded Over 30 Days
Délai: Change from Month 1 to Month 4
|
Headache Severity was recorded for every headache day on a scale of 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Average headache severity was averaged across all headache days for each month.
|
Change from Month 1 to Month 4
|
|
The Pain Catastrophizing Scale
Délai: Change from Month 1 to Month 4
|
13-item self-report measure that conveys a participant's level of pain-related, catastrophic thinking during painful experiences.
Total scores range from 0-52, with higher scores indicating higher levels of catastrophizing.
|
Change from Month 1 to Month 4
|
|
Chronic Pain Acceptance Questionnaire
Délai: Change from Month 1 to Month 4
|
20-item, self-report measure of pain-related acceptance.
Total scores range from 0-156 with higher scores indicating higher pain acceptance.
|
Change from Month 1 to Month 4
|
|
Five Facet Mindfulness Questionnaire
Délai: Change from Month 1 to Month 4
|
39-item self-report instrument assessing mindfulness.
Total scores range from 39-195, with higher scores indicating higher levels of mindfulness.
|
Change from Month 1 to Month 4
|
|
Headache Specific Locus of Control
Délai: Change from Month 1 to Month 4
|
33-item measure designed to assess the extent to which individuals with recurrent headaches expect that the occurrence, worsening, and improvement of their headaches are influenced primarily by their own behavior, by chance or fate, or by the actions of medical professionals.
Total scores range from 33-165, with higher scores indicating more external (vs.
internal) locus of control.
|
Change from Month 1 to Month 4
|
|
Headache Management Self-efficacy Scale
Délai: Change from Month 1 to Month 4
|
25-item self-report scale designed to capture the confidence a patient believes they have in their own abilities to prevent headache episodes and manage their pain.
Total scores range from 25-175, with higher scores indicating higher levels of self-efficacy
|
Change from Month 1 to Month 4
|
|
NIH PROMIS Depression Short Form
Délai: Change from Month 1 to Month 4
|
8-item self-report measure that assesses emotional distress in the past week focusing on negative mood and negative self-views.
Scores are normed using T-scores (M = 50, SD = 10) with higher scores indicating higher levels of depressive symptoms.
|
Change from Month 1 to Month 4
|
|
NIH PROMIS Anxiety Short Form
Délai: Change from Month 1 to Month 4
|
8-item self-report measure that assesses emotional distress in the past week focusing on fear, worry and hyper-arousal.
Scores were normed using T-scores (M = 50, SD = 10) with higher scores indicating higher levels of anxious symptoms.
|
Change from Month 1 to Month 4
|
|
Average Monthly Migraine Disability Index
Délai: Change from Month 1 through Month 4
|
A daily 4-item measure of migraine related disability.
Scores range from 0-10, with higher scores indicating higher levels of disability.
Scores are averaged across all headache days recorded each month.
|
Change from Month 1 through Month 4
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 juillet 2015
Achèvement primaire (Réel)
1 octobre 2018
Achèvement de l'étude (Réel)
1 février 2019
Dates d'inscription aux études
Première soumission
8 mai 2015
Première soumission répondant aux critères de contrôle qualité
11 mai 2015
Première publication (Estimation)
14 mai 2015
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
12 octobre 2020
Dernière mise à jour soumise répondant aux critères de contrôle qualité
17 septembre 2020
Dernière vérification
1 septembre 2020
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2015-4684
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .